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Background: There are important inter-individual variations in the incidence and severity
of acute pancreatitis in patients with severe hypertriglyceridemia. Several genes involved
in triglyceride-rich lipoprotein metabolism or serine proteases pathways are known to
influence the risk of pancreatitis.
Aim: To evaluate the association between genes regulating serine proteases,
chymotrypsin C (CTRC) and serine peptidase inhibitor kazal type1 (SPINK1), and
recurrence of hospitalizations for acute pancreatitis or severe abdominal pain in patients
with Lipoprotein Lipase Deficiency (LPLD), a rare and extrememonogenic model of severe
hypertriglyceridemia and pancreatitis.
Method: The CTRC and SPINK1 genes promoter and coding regions sequencing has been
performed in a sample of 38 LPLD adults (22 men and 16 women) and 100 controls (53
men and 47 women). Estimation of the association of CTRC and SPINK1 gene variants or
combinations of variants with history of hospitalizations for pancreatitis or acute abdominal
pain in LPLD was investigated using non-parametric analyses with correction for multiple
testing and logistic regression models controlling for age, gender, family history, and life
habits.
Results: Gene sequencing followed by genotype-stratified analyses of the CTRC and
SPINK1 genes in LPLD and controls revealed a positive association between recurrence
of hospitalizations and the rs545634 (CTRC)—rs11319 (SPINK1) combination [OR = 41.4
(CI: 2.0–848.0); p = 0.016]. In all models, a positive family history of pancreatitis was
a significant predictor of recurrent hospitalizations independently of the contribution of
SPINK1 or CTRC (p < 0.001).
Conclusion: These results suggest that a positive family history of pancreatitis and
genetic markers in the serine protease pathways could be associated with a risk of
recurrent hospitalization for acute pancreatitis in severe hypertriglyceridemia due to LPLD.
Keywords: severe hypertriglyceridemia, lipoprotein lipase deficiency (LPLD), pancreatitis, CTRC gene, SPINK1
gene, LPL gene
INTRODUCTION
Very severe hypertriglyceridemia (defined as fasting plasma TG
concentration >10mmol/L or 900mg/dl) increases the risk of
acute pancreatitis and has a prevalence of approximately 1/600
in North America (Johansen et al., 2011). Both severe hyper-
triglyceridemia and acute pancreatitis are associated with impor-
tant clinical and socio-economic burden (Gaudet et al., 2013).
However, there are important inter-individual variations in the
incidence and severity of acute pancreatitis in patients with severe
hypertriglyceridemia. Although rare, some extreme forms of
severe hypertriglyceridemia and pancreatitis risk exist. This is the
case of Lipoprotein Lipase Deficiency (LPLD) [MIM: 238600—
Familial hyperchylomicronemia]. LPLD is a rare monogenic dis-
ease transmitted on an autosomal recessivemode (Monsalve et al.,
1990; Ma et al., 1991; Mattei et al., 1993; Brunzell and Deeb,
2001). It is associated with recurrent, severe abdominal pain,
increased risk of acute pancreatitis and other morbidities such as
pulmonary embolism-like syndrome, coronary heart disease with
or without atherosclerosis, and metabolic consequences of pan-
creatic insufficiency, including insulinopenic diabetes (Brunzell
and Deeb, 2001; Tremblay et al., 2011). Although rare, LPLD
is the most common form of the Familial Chylomicronemia
Syndrome (FCS). The estimated worldwide prevalence of LPLD
is 1–2:1,000,000 (Fredrickson et al., 1978). Numerous loss-of-
function lipoprotein lipase gene (LPL) [MIM:609708] mutations
were identified, but only a small number are null alleles, rec-
ognized to be responsible to the markedly reduced or absent
lipoprotein lipase activity observed in LPLD (Brunzell and Deeb,
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2001). LPLD results in chylomicrons accumulation and severe
hypertriglyceridemia (>10mmol/L) in the fasting state, and is
associated with characteristic clinical signs such as eruptive xan-
thomas, lipaemia retinalis, and hepatosplenomegaly (Brunzell
and Deeb, 2001). Other causes of FCS are documented, such
as apolipoprotein C-II (APOC2), glycosylphosphatidylinositol-
anchored high density lipoprotein-binding protein 1 (GPIHBP1),
lipase maturation factor 1 (LMF1) or apolipoprotein A-V
(APOA5) gene deficiencies, which all result in functional LPLD
(Surendran et al., 2012). Currently, no available lipid-lowering
drug therapy is effective to control the risk associated with LPLD,
and affected patients typically do not respond to fibrates or niacin
(Brisson et al., 2010; Zhou and Sahin-Toth, 2011; Beer et al.,
2012). LPLD, like all other causes of FCS, is predominantly treated
by severe dietary fat restriction and the use of medium-chain
triglycerides (MCT) (Brunzell and Deeb, 2001), which does not
fully eliminate the risk of pancreatitis or disease progression,
while interfering with patient’s quality of life on a daily basis.
Recently, LPL gene replacement therapy (Gaudet et al., 2010,
2012) has been approved in Europe for severely affected LPLD
patients. New emerging classes of treatments are in clinical devel-
opment for FCS, including (among others) DGAT-1 inhibitors
(Meyers et al., 2012), apoC3 antisense therapy, MTP inhibitors
(Sacks et al., 2013) and peptide linker technologies.
As inmanyMendelian diseases, important variations are noted
in the clinical expression of LPLD. In particular, the incidence
and the severity of abdominal pain and acute pancreatitis vary
importantly across an individual’s lifespan and between affected
individuals, even in the same family. Although the pancreatitis
risk is extremely high in LPLD (Tremblay et al., 2011), some
patients do not experience a crisis before advanced age while oth-
ers were frequently hospitalized since young age or eventually
die from complications. Such heterogeneity in LPLD phenotypic
expression complicates the individualization of risk evaluation
and stratification.
The genetic basis of pancreatitis is now well documented and
numerous candidate genes have been reported (Chen and Ferec,
2009; Whitcomb, 2010, 2013). All these genes could theoritically
influence the trajectory of pancreatitis risk in LPLD. The vari-
ability of pancreatitis expression in LPLD is obviously complex
and can also be affected by several environmental factors and by
epigenetic regulatory mechanisms such as methylation, and/or
microRNA (Jiang et al., 2004; Chahwan et al., 2011). In this study,
we used a candidate gene approach to evaluate the association
between the recurrence of hospitalization for acute pancreatitis
or severe abdominal pain in LPLD and genes known to con-
tribute to pancreatitis susceptibility. Specifically, we have selected
the chymotrypsinogen C (CTRC) and serine protease inhibitor
Kazal-type 1 (SPINK1) genes based on their important physio-
logical role in serine proteases regulation and because they might
have a functional relation with LPLD through the high density
lipoprotein (HDL) particle which is significantly affected in this
disease. In particular, the HDL cholesterol concentration, and the
number of HDL particles are significantly decreased in LPLD.
HDL is an efficient carrier of alpha(1)-antitrypsin and has been
reported to play a significant role in proteases inhibition.
MATERIALS AND METHODS
SUBJECTS
A total of 138 Caucasian adults have participated in this study:
100 normolipemic controls and 38 genetically confirmed patients
with LPLD. All LPLD patients were identical-by-descent (IBD)
homozygotes or compound heterozygous for null alleles in the
LPL gene and presented fasting plasma TG values >10mmol/L
and clinical characteristics of FCS (Gaudet et al., 1998; Gagné
and Gaudet, 2007; Tremblay et al., 2011). Null LPL alleles are
associated with <5% normal LPL activity. Fasting plasma TG,
cholesterol, non-esterified fatty acids, and apolipoprotein B (apo
B) were measured as previously described (St-Pierre et al., 2001).
Among the 38 LPLD participants, 18 had a history of recur-
rent (≥5) hospitalizations for severe abdominal pain or acute
pancreatitis whereas 8 had not yet been hospitalized for such con-
dition. Overall, approximately 80% of LPLD patients had already
suffered from at least one episode of pancreatitis or abdominal
pain requiring hospitalization and the number of hospitaliza-
tions per individual ranged between 0 and 96. Calculation of the
number of hospitalizations for pancreatitis or severe abdominal
pain was performed by questionnaire and by reviewing patient’s
medical charts. Applying the criteria of the Atlanta classification
for pancreatitis (Banks et al., 2013), the hospitalizations having
been considered in this study group all definite, probable and
suspected pancreatitis episodes. Hospitalizations for conditions
clearly not suspected to be related to FCS (eg., appendicectomy,
parietal pain) were not considered in the analyses. The fam-
ily history was considered “positive” when at least one known
relative (available in our database) has already been hospital-
ized for acute pancreatitis. All LPLD patients have been followed
in a Lipid Clinic, received nutritional counseling and were pre-
scribed a strict type-1 adapted low fat diet. This study has
been approved by the Local Ethics Review Board in accordance
with the Declaration of Helsinki and all subjects gave informed
consent.
CTRC AND SPINK1 SEQUENCING
DNA has been extracted from blood leukocytes of all partici-
pants using Qiagen kit and following manufacturer’s instruction
(Qiagen Inc., Valencia, CA, USA). CTRC [1p36.21—GeneID:
11330] and SPINK1 [5q32—GeneID: 6690] sequences infor-
mation were obtained from UCSC Genome Browser (http://
genome.ucsc.edu/, University of California, Santa Cruz, CA,
USA). For CTRC, the PCR was divided into seven regions
that spanned 3.1 kb, covering all eight coding and promoter
sequences (Figure 1). For SPINK1, the PCR was divided into four
regions that spanned 2.2 kb, covering all four coding and pro-
moter regions (Figure 1). Analysis of sequences were performed
with CodonCode Aligner (http://www.codoncode.com/aligner/,
CodonCode Corporation Dedham, MA, USA). Oligonucleotide
sequences as well as PCR amplification specific annealing temper-
atures are listed in the Supplementary Table 1. The PCR reactions
were done in 25µL volume containing 0–1mM of Magnesium
Chloride, 1X of Qiagen HotStart Taq PCR Buffer or 1X of NEB
Taq PCR Buffer, 0.25mM of dNTPs, 1U/reaction of HotStart Taq
DNA polymerase (Qiagen, Valencia, CA, USA or New England
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FIGURE 1 | Schematic representation of the LPL, CTRC, and
SPINK1 genes structure. The gene representation is based on UCSC
Genome Browser (http://genome.ucsc.edu/, February 2009, Santa Cruz,
CA, USA) and Ensembl (http://uswest.ensembl.org/index.html,
september 2013, Cambridge, United Kingdom), and is not scaled.
CTRC and SPINK1 sequenced regions and identified variants are
indicated. Complementary informations on sequenced regions are
avaible in Supplementary Table 1.
Biolabs Inc., Ipswich, Ma, USA), 0.2µM of each primer and 20
ng/µl human genomic DNA. The PCR amplification was per-
formed at 95◦C for 10min, 35 cycles of: first, 94◦C during 30 s,
secondly, annealing temperature for 30 s and thirdly, 72◦C for
30 s. Finally, one cycle at 72◦C for 7min. Amplification prod-
ucts were purified with multiscreen PCR plates (MSNU 030
PCR, Millipore Corporation, Bedford, Ma, USA). Sequencing
reactions were done in 10µL volume containing 2µL of puri-
fied and diluted PCR product, 0.3µL of BigDye terminator
v1.1 (Applied Biosystem Inc., Foster City, CA, USA), 1.75µL
of BigDye Terminator Sequencing Buffer 5X (Applied Biosystem
Inc., Foster City, CA, USA) and 0.5µL of the forward or reverse
PCR primer (Supplementary Table 1). The sequencing reaction
cycles were done following manufacturer’s instructions (BigDye®
Terminator v1.1 Cycle Sequencing Kit). Reaction sequences were
precipitated in 3M of sodium acetate (Ambion®, Foster City,
CA, USA) and 95% ethanol, resuspended in 10µL of Hi-Di™
Formamide (Applied Biosystem Inc., Foster City, CA, USA)
and analyzed on ABI PRISM 3100 Genetic Analyzer (Applied
Biosystem Inc.).
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS software (IBM
Corporation, SPSS Statistics for Windows, Versions 11.5.0, and
21.0, Armonk, NY, USA). Continuous variable comparisons
between the different phenotypes were done using Kruskal-
Wallis non-parametric tests combined to Mann-Whitney tests
to perform inter-group comparisons. P-values are reported after
Bonferroni correction for multiple testing. Chi-Square tests were
used to compare dichotomic variables as well as minor allele fre-
quencies and genotypes distribution between studied groups, and
z-test was performed to inter-group comparisons. P-values were
also adjusted using the Bonferroni method. For interaction anal-
yses, significance level was fixed at p ≤ 0.005 since we have tested
10 SNPs combinations. Estimation of the association of CTRC
and SPINK1 variants or combinations with recurrent (≥5) hos-
pitalizations for pancreatitis or acute abdominal pain in LPLD
was also investigated usingmultinominal logistic regressionmod-
els controlling for age, gender, and smoking status. Subjects with
known alcohol abuse or known to be non-compliant to the diet
were excluded from the study. In regression models, compar-
isons were made using normolipidemic controls as the reference.
Results are reported for the groups of LPLD patients with ≥5
or <5 hospitalizations as odds ratio (OR) and 95% confidence
interval (CI) at a significance level fixed at p < 0.05.
RESULTS
The characteristics of the two LPLD groups (defined on the basis
of the number of hospitalizations for pancreatitis or abdomi-
nal pain) and controls are presented in Table 1. LPLD patients
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Table 1 | Characteristics of the Participants.
Controls Severe hypertriglyceridemia (LPLD) p-valuef
<5 hospitalizations ≥5 hospitalizations
n = 100 n = 20 n = 18
DEMOGRAPHICS
Age [years; geometric mean (SD)] 41.8 (16.3) 43.2 (17.1) 53.2 (13.6)2 0.023
Gender [M/F (ratio)] 53/47 (1.1) 12/8 (1.5) 10/8 (1.3) 0.843
Body mass index [kg/m2; geometric mean (SD)] 24.0 (4.0) 22.7 (5.3) 22.6 (3.0) 0.303
Smoking status [n (%)]a 56 (56.0) 11 (68.8) 14 (93.3)2 0.020
Family history of pancreatitis [n (%)]b 6 (6.4) 7 (46.7)1 13 (92.9)2,3 <0.001
Hospitalizations [median (range)]c 0 1 (0–4) 16 (5–96)3 <0.001
FASTING LIPID PROFILE
Total triglycerides [mmol/L; median (range)] 0.9 (0.3–1.8) 27.7 (14.9–60.8)1 33.3 (14.4–75.3)2 <0.001
Total cholesterol [mmol/L; median (range)] 4.2 (3.0–6.8) 6.9 (3.0–18.9)1 6.5 (3.6–15.1)2 <0.001
LDL-cholesterol [mmol/L; median (range)] 2.1 (1.2–3.5) 0.6 (0.2–2.3)1 0.5 (0.2–1.5)2 <0.001
HDL-cholesterol [mmol/L; median (range)] 1.3 (0.7–2.2) 0.4 (0.2–0.6)1 0.3 (0.2–0.5)2 <0.001
Plasma NEFA [mmol/L; median (range)] 0.5 (0.1–1.1) 0.5 (0.0–2.4) 0.5 (0.2–1.1) 0.629
Total apolipoprotein B [mmol/L; median (range)] 0.7 (0.4–1.4) 0.7 (0.3–1.8) 0.6 (0.3–2.1) 0.934
SNP DISTRIBUTIONd
CTRC rs545634 13 (0.071) 1 (0.025) 5 (0.139) 0.158g
rs10927786 27 (0.175) 10 (0.275) 9 (0.333) 0.055g
SPINK1 rs11319 6 (0.003) 1 (0.025) 4 (0.111) 0.063g
SNP COMBINATION DISTRIBUTIONe
CTRC + SPINK1 rs545634—rs11319 1 (1.0) 0 4 (22.2)2,3 <0.001g
rs10927786—rs11319 1 (1.0) 0 0 0.847g
Abbreviations used: CTRC, Chymotrypsin C; F, Female; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; LPLD, Lipoprotein lipase deficiency; M, Male;
MAF, Minor allele frequency; NEFA, Non-esterified fatty acids; SD, Standard deviation; SNP, Single Nucleotide Polymorphism; SPINK1, Serine peptidase inhibitor,
kazal type 1.
aSubjects who ever smoked (current or ex-smokers).
bAt least one member of the family who had at least one pancreatitis episode. Complete family history was not available for all controls and LPLD subjects.
cCalculated on 13 subjects in ≥5 hospitalizations group.
d Presented as number of heterozygous and homozygous mutant subjects (MAF).
ePresented as number of subjects possessing at least one mutant allele in both identified variants (%) (meaning all subjects are heterozygous or heterozy-
gous/mutant homozygous).
f Kruskal-Wallis (for continuous variables) and Pearson Chi-Square (for dichotomic variables). Group comparisons were done using Mann-Whitney or test-z adjusted
with Bonferroni method. 1indicates significant difference (p ≤ 0.05) between <5 hospitalizations vs. controls; 2between ≥5 hospitalizations.vs. controls; and
3between <5 hospitalizations vs. ≥5 hospitalizations.
gChi-square or Fischer exact tests p-value. Group comparisons were done using test-z adjusted with Bonferroni method. 1indicates significant difference (p ≤ 0.05)
between <5 hospitalizations vs. controls; 2between ≥5 hospitalizations vs. controls; and 3between <5 hospitalizations.vs. ≥5 hospitalizations.
had significantly higher total triglyceride and cholesterol levels,
and lower LDL-C and HDL-C than controls. Both LPLD groups
were comparable for other lipid-lipoprotein variables, includ-
ing total cholesterol, HDL-C, non-esterified fatty acids and total
apolipoprotein B. LPLD subjects with recurrent hospitalizations
were older, in addition to present a higher proportion of smokers
than controls. They also presented a greater proportion of positive
family history of pancreatitis than controls and LPLD subjects
with <5 hospitalizations. All groups were comparable for body
mass index.
Table 1 also presents the compared frequency of theCTRC and
SPINK1 variants showing an association with recurrent hospital-
izations for pancreatitis or acute abdominal pain while Table 2
presents the characteristics of all CTRC and SPINK1 variants
(n = 15) identified through gene sequencing in the different
groups. All identified variants are single nucleotide polymor-
phisms (SNP) located in coding, non-coding or untranslated
regions (Table 2 and Figure 1). The Supplementary Table 2
presents the associations in more details. Minor allele frequency
comparisons between the studied groups revealed a trend of
association with recurrent pancreatitis for only three SNPs (p-
values< 0.2) (Table 1). Of note, among the eight LPLD individu-
als who had never been hospitalized for pancreatitis, the rs545634
was not observed while three heterozygous were observed for
rs10927786 and one heterozygous for rs11319. We then per-
formed two-by-two interaction analyses among the associated
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SNPs (Table 1). At a significance level of 0.005, only one SNP
combination, CTRC (rs545634) and SPINK1 (rs11319), showed
a positive association after correction for multiple testing (p <
0.001). Genotype-stratified analyses confirmed that all subjects
carrying this combination were heterozygotes (p < 0.001). We
have then evaluated the association of this CTRC (rs545634) and
SPINK1 (rs11319) combination with recurrent pancreatitis in
logistic regression analysis, including age, gender and smoking
status as covariates (Table 3). Results of multivariate analyses con-
firmed the association of the rs545634-rs11319 SNPs combina-
tion with an increased odd of recurrent hospitalizations for acute
pancreatitis or severe abdominal pain (OR = 41.4, p = 0.016).
A positive family history of pancreatitis was also a significant
covariate of recurrent hospitalizations in all groups (p < 0.001).
When the family history was included in the regression mod-
els, the contribution of SPINK1-CTRC combination to the risk
Table 2 | Genetic Characteristics of the CTRC and SPINK1 Variants Identified.
Gene [GeneID] Identified varianta Base
change
Gene locationb Amino acid
predicted
substitution
MAF Observed genotypes HWE
p-valuef
HMZcommon HTZ HMZrare
CTRC rs4661626 A>G Promoter 15764150 – – 0.412 51 58 27 0.163
1p36.21 rs144717165 T>C Promoter 15764869 – – 0.004 137 1 0 0.966
[11330] rs183658182 T>C Promoter 15764902 – – 0.004 137 1 0 0.966
rs497078 T>C Exon 3 15767036 S G60G 0.083 116 21 1 0.963
rs41303875 A>G Intron 4 15769845 – – 0.007 136 2 0 0.932
rs10803384 A>C Intron 5 15770101 – – 0.226 84 44 9 0.333
rs545634 A>G Intron 5 15770102 – – 0.073 118 18 1 0.733
rs10927786 T>G Intron 6 15772057 – – 0.210 92 34 12 0.002
rs121909293c T>C Exon 7 15772212 NS R254W 0.004 137 1 0 0.966
rs555015 A>G Intron 7 15772933 – – 0.500 34 70 34 0.865
SPINK1 rs62378571 T>C Promoter 147211947 – – 0.147 98 36 2 0.520
5q32 rs17107315d G>A Exon 3 147207678 NS N34S 0.011 135 3 0 0.897
[6690] rs141634296e A>G Exon 3 147207585 NS R65Q 0.004 137 1 0 0.966
CM016009 T>C Exon 3 147207585 NS R65W 0.004 137 1 0 0.966
rs11319 T>C 3’UTR 147204192 – – 0.040 127 11 0 0.626
Abbreviations used: MAF, Minor allele frequency; HMZcommon, Homozygous for the common allele; HTZ, Heterozygous; HMZrare, Homozygous for the rare mutant
allele; HWE, Hardy-weinberg equilibrium; NS, non-synonymous; S, Synonymous; SNP, Single nucleotide polymorphism; UTR, Untranslated region.
aUCSC SNP reference number (http://genome.ucsc.edu/, February 2009).
bPosition in UCSC Genome Browser (http://genome.ucsc.edu/, February 2009).
cVariant reported to be associated with chronic pancreatitis. (Masson et al., 2008; Zhou and Sahin-Toth, 2011; Beer et al., 2012).
d Variant reported to be associated with chronic pancreatitis, (Witt et al., 2000; Chen and Ferec, 2009) and acute pancreatitis. (Sanchez-Ramirez et al., 2012).
eVariant reported to be associated with chronic pancreatitis. (Boulling et al., 2007; Kiraly et al., 2007).
f Chi-square test p-value. Variant highlighted in gray is not in HWE (p ≤ 0.001).
Table 3 | Association of CTRC and SPINK1 SNPs Combination and Family History with Recurrence (≥5) of Hospitalizations for Pancreatitis in
Severe Hypertriglyceridemia due to LPLD.
Modelsa LPLD subjects
<5 hospitalizations ≥5 hospitalizations
OR [95% CI] p-value OR [95% CI] p-value
CTRC-SPINK1 SNPs combination NA – – 41.4 2.0–848.0 0.016
Family history of pancreatitis 19.6 4.3 – 90.1 <0.001 410.6 29.4–5733.8 <0.001
CTRC-SPINK1 SNPs combination + family NA – – 148.6 1.5–14537.5 0.032
history of pancreatitis
Abbreviations used: CI, 95% confidence interval; CTRC, Chymotrypsin C; LPLD, Lipoprotein lipase deficiency; NA, not applicable (the test is not valid due to the
absence of cases), OR, odd ratio; SPINK1, Serine peptidase inhibitor, kazal type 1.
aMultinominal regression models tested, including age, gender and smoking status as covariates. The reference category are the normolipemic control
subjects (Table 1).
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of hospitalization for pancreatitis or abdominal pain remained
significant (p = 0.032).
DISCUSSION
Both pancreatitis and hypertriglyceridemia are complex traits and
inter-individual variations are regularly observed in the expres-
sion of pancreatitis in patients with severe hypertriglyceridemia.
Such differences are noticed even in a homogeneous group of
individuals affected by LPLD, a disease characterized by extreme
plasma triglyceride values and high risk of pancreatitis (Brunzell
and Deeb, 2001; Tremblay et al., 2011). LPLD is a very rare dis-
ease and we thus report data on one of the largest sample of
LPLD patients having been ever published. In this sample, we
observed important variations in term of pancreatitis morbid-
ity (assessed by the recurrence of hospitalizations), despite the
fact that all patients were carrying the same LPL gene defect.
Indeed, approximately 80% of LPLD adults in this study had
been hospitalized at least once for acute pancreatitis (range: 1–96)
but 20% had never suffered from pancreatitis, even at age >50.
The results presented herein suggest that genetic markers in the
serine protease pathways could influence the risk of recurrent
hospitalizations for acute pancreatitis or acute abdominal pain
in LPLD.
Clinically, the diagnosis of acute pancreatitis requires two of
the following criteria: abdominal pain suggestive of acute pan-
creatitis, serum amylase and/or lipase activity at least three times
greater than the upper limit of normal, and characteristic find-
ings of acute pancreatitis on abdominal ultrasonography or on
contrast-enhanced computed tomography scanning or magnetic
resonance imaging (Frossard et al., 2008; Banks et al., 2013).
However, due to severe chylomicronemia, FCS is by nature asso-
ciated with spurious estimation of several laboratory values and
patients can present with pancreatitis and normal amylase or
lipase values. Furthermore, imaging results were not available
in all patients medical files. This might lead to underestimating
the number of definite pancreatitis episodes in these patients. To
overwhelm this issue, we considered all cases of hospitalizations
for acute abdominal pain which were suggestive of pancreati-
tis. This includes all definite, probable and suspected cases of
pancreatitis.
Family history is an important predictor of risk of sev-
eral lipid-related diseases, including pancreatitis. In this study,
LPLD patients with ≥5 hospitalizations for pancreatitis or severe
abdominal pain presented at least twice the proportion of positive
family history of pancreatitis than that observed in patients with
less hospitalizations and controls. The family history is obviously
not reflecting the genetic background only and takes into account
shared life habits and the environemental background.
Although hereditary forms of pancreatitis exist (LaRusch
et al., 2012), the majority of genes having been associated with
pancreatitis explain the predisposition, rather than the cause, of
acute pancreatitis. All FCS causing genes, including LPL are well-
documented pancreatitis susceptibility genes. Pancreatitis is a
complex disease and the mechanisms explaining the pancreatitis
risk in LPLD are not clearly understood. One hypothesis is that
large chylomicrons lodged in pancreatic capillaries expose them
to pancreatic lipase, with the subsequent release of free fatty acids
through the hydrolysis of chylomicron-associated triglycerides.
Local high concentrations of free fatty acids are thought to dam-
age pancreatic cells leading to pancreatitis (Ross et al., 2004, 2006;
Rip et al., 2005, 2006; Gaudet et al., 2010). Another hypothesis
is that phospholipids and oxidized phospholipids at the surface
of buyant-chylomicrons once hydrolyzed by phospholipase
serve as triggers for proteases. In all cases, if enough proteases
become activated intracellularly, they can overwhelm the first
line of defense (pancreatic secretory trypsin inhibitor) and resist
backup defenses (proteolytic degradation). Activated cationic
trypsin can then trigger the entire zymogen activation cascade
(Frossard et al., 2008). It is possible that mutations in CTRC and
SPINK1 genes contribute to this process and further increase
the pancreatitis risk conferred by LPLD by either increasing the
level of activated proteases, blocking active site of trypsin or
decreasing proteases degradation. Indeed, mutant variants in
CTRC and SPINK1 genes are known to contribute to pancreatitis
susceptibility (Chen and Ferec, 2009; Whitcomb, 2010). CTRC
encodes the protease chymotrypsin C, a protease produced in
small quantities by the acinar cells and found in an inactive form
in the zymogen granules (Szmola and Sahin-Toth, 2007), which
degrades trypsin when trypsinogen is prematurely activated in
the pancreas (Szmola and Sahin-Toth, 2010). Genetic variations
in CTRC can predispose to chronic pancreatitis by diminishing
its protective trypsin-degrading activity (Szmola and Sahin-
Toth, 2007; Rosendahl et al., 2008; Whitcomb, 2010). SPINK1
encodes pancreatic secretory trypsin inhibitor, which prevents
trypsin-catalyzed premature activation of zymogens within
the pancreas and the pancreatic duct (Chen and Ferec, 2009;
Ohmuraya and Yamamura, 2011; Kume et al., 2012). Mutations
in this gene have been associated with hereditary pancreatitis
(Ohmuraya and Yamamura, 2011; Ohmuraya et al., 2012), and
it is thought to function in the prevention of trypsin-catalyzed
premature activation of zymogens within the pancreas. CTRC
and SPINK1 have pleiotropic functions but their role in serine
proteases (trypsin and chymotrypsin) physiology is shared in
common. This might explain why the effect of the combination
of variants in these two genes on risk of pancreatitis in LPLD was
more pronounced than single variants effect in the present study:
CTRC-rs545634, located in the 5th intron, could be responsible
of an alternate splicing site which would affect this enzyme’s
integrity and its inhibitory effect, combined to SPINK1-rs11319,
located in the 5’UTR, that could affect mRNA stability and
be responsible of a lesser production of this trypsin inhibitor,
may be compatible with an increased pancreatitis risk. Further
functional studies on these variants are needed to elucidate the
role of their mutant allele in this hypothetic loss of inhibitory
function responsible of their associated pancreatitis risk
in LPLD.
Trypsin and chymotrypsin are two structurally similar ser-
ine proteases synthesized in the pancreas as inactive zymogen
precursors (trypsinogen and chymotrypsinogen) secreted in the
duodenum via the pancreatic duct and converted to the mature,
active enzyme by proteolysis (Frossard et al., 2008; Whitcomb,
2010). They recognize different protein substrates. Trypsinogen
and chymotrypsinogen also enter the bloodstream, where they
can be detected in serum (Artigas et al., 1981). In blood, serine
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proteases of the trypsin-like family have long been recognized
to be critical effectors of biological processes as diverse as blood
coagulation, fibrinolysis, and immunity (Antalis et al., 2011).
Serum trypsin levels have been shown to be significantly higher
in acute pancreatitis patients than in controls (Artigas et al.,
1981). Mass spectrometry and western blotting have shown that
HDL are efficient carriers of alpha(1)-antitrypsin (Ortiz-Munoz
et al., 2009). HDL-associated alpha(1)-antitrypsin appears to
be able to inhibit trypsin activity, extracellular matrix degra-
dation, cell detachment, and apoptosis induced by proteases
in human vascular smooth muscle cells. The number of HDL
particles and their cholesterol content is in general very low
in presence of severe hypertriglyceridemia, a feature systemati-
cally observed in LPLD. It is possible that low HDL-associated
alpha(1)-antitrypsin is a factor contributing to LPLD mor-
bidity, including hepatomegaly and deleterious liver effects, in
presence of mutant alleles in protease-regulating genes, such
as CTRC and SPINK1. Clinically, serum serine proteases have
been directly associated with triglycerides metabolism, includ-
ing GPIHPB1-related factors and glycosylphosphatidylinositol
linkage (Deeg and Bowen, 2002). Severe hypertriglyceridemia
induced by PEG-L-Asparaginase in patients treated for acute
lymphocytic leukemia can induced acute pancreatitis in patients
undergoing chemotherapy (Konig and Malek, 2012). This has
been associated with increased levels of serum trypsin and elastase
10 and 20 days after beginning L-asparaginase therapy (Shimizu
et al., 1998). Alcohol abuse is associated with both hypertrigly-
cridemia, and proteases activation (Joly et al., 1992). It is one of
the most common cause of acute pancreatitis (Thrower et al.,
2008). In this study, we excluded all known cases of alcohol
abuse, although it is almost not viable long term in FCS due to
nature of the disease and the huge risk of heavy alcohol con-
sumption for these patients. The links between the proteases
networks and lipid metabolism are complex and the connection
with pancreatitis risk and other morbidities in LPLD remain to be
documented.
This study has limitations. LPLD is an ultra-rare, and extreme
cause of hypertriglyceridemia and is thus not representative of all
causes of severe hypertriglyceridemia. The rarity of LPLD, implies
that we have to deal with small sample size which also limits the
power of association studies. Despite this, the results suggest that
genetic markers in the protease cascade could be associated with
the expression of pancreatitis in LPLD. However, functional anal-
yses were not performed in this study and we cannot infer at
this point that there is a physiological association between pro-
tease regulators and the recurrence of pancreatitis in presence of
severe hypertriglyceridemia. Our findings need to be validated
and replicated in larger LPLD and severe hypertriglyceridemia
cohorts and the functional effect of identified variants needs to
be characterized before this SNP-combination could be consid-
ered as a clinical biomarker of recurrence of pancreatitis in LPLD.
Since other genes are known to confer pancreatitis susceptibility,
additional analyses are needed to understand the complex genetic
architecture of pancreatitis in LPLD. Such studies, including
whole genome sequencing, resequencing of extremes, functional
gene expression analyses, physiologicial andmetabolic studies, are
actually underway.
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